Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 May;88(5):2019-2034.
doi: 10.1111/bcp.15155. Epub 2021 Dec 21.

Efficacy of targeted therapy in patients with HER2-positive non-small cell lung cancer: A systematic review and meta-analysis

Hong-Xia Wu  1 , Kai-Quan Zhuo  2 , Ke Wang  1
Affiliations
Meta-Analysis

Efficacy of targeted therapy in patients with HER2-positive non-small cell lung cancer: A systematic review and meta-analysis

Hong-Xia Wu et al. Br J Clin Pharmacol. 2022 May.

Abstract

Anti-human epidermal growth factor receptor 2 (HER2) therapy is an effective treatment for HER2-positive gastric and breast malignancies. However, the efficacy of HER2-targeted therapy in non-small cell lung cancer (NSCLC) patients with HER2 alterations remains controversial. We searched studies on HER2-targeted therapy in NSCLC patients that reported objective response rate (ORR), disease control rate (DCR) and progressionfree survival (PFS) published from database inception to 30 May 2021. A total of 32 trials involving 958 patients were included. The ORRs of HER2-TKIs targeted therapy, humanised monoclonal antibody, trastuzumab-based treatment and antibody-drug conjugate (ADC) (T-DM1) were 22% (95% CI 11-31), 23% (95% CI 20-65), 26% (95% CI 14-39) and 16% (95% CI _6-37), while that of ADC (DS-8201) was 60% (95% CI 35-85). The DCRs of these groups were 59% (95% CI 49-69), 39% (95% CI _9-88), 63% (95% CI 37-89), 31% (95% CI 4-58) and 87% (95% CI 62-112), respectively. In the subgroup analysis, numerically higher ORRs and DCRs were observed in the poziotinib (38%; 75%) and pyrotinib (35%; 83%) groups. The median PFSs of these groups were 5.51 months, 3.09 months, 4.61 months, 2.65 months and 12.04 months, respectively. HER2-targeted therapy can be considered an acceptable treatment strategy for NSCLC patients with HER2 alterations. In particular, ADC (DS-8201), pyrotinib and poziotinib demonstrated promising anti-tumour activity in HER2-positive NSCLC.

Keywords: ERBB2; HER2; biomarkers; meta-analysis; non-small cell lung cancer; review; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Flowchart diagram of selected searches for inclusion in meta‐analysis
FIGURE 2
FIGURE 2
Forest plot of cumulative incidence of ORR among patients treated with HER2‐TKIs targeted therapy
FIGURE 3
FIGURE 3
Forest plot of cumulative incidence of ORR among patients treated with HER2‐targeted therapy
FIGURE 4
FIGURE 4
Forest plot of cumulative incidence of DCR among patients treated with HER2‐TKIs targeted therapy
FIGURE 5
FIGURE 5
Forest plot of cumulative incidence of DCR among patients treated with HER2‐targeted therapy
FIGURE 6
FIGURE 6
Forest plot of PFS among patients treated with HER2‐TKIs targeted therapy
FIGURE 7
FIGURE 7
Forest plot of PFS among patients treated with HER2‐targeted therapy
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394‐424. 10.3322/caac.21492 Erratum in: CA Cancer J Clin. 2020;70(4):313. - DOI - PubMed
    1. Kalemkerian GP, Narula N, Kennedy EB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice guideline update. J Clin Oncol. 2018;36(9):911‐919. 10.1200/JCO.2017.76.7293 - DOI - PubMed
    1. Ettinger DS, Wood DE, Aisner DL, et al. NCCN guidelines insights: non‐small cell lung cancer, version 2.2021. J Natl Compr Canc Netw. 2021;19(3):254‐266. 10.6004/jnccn.2021.0013 - DOI - PubMed
    1. Alexander SP, Kelly E, Marrion N, et al. The Concise Guide to PHARMACOLOGY 2019/20: Introduction and other protein targets. Br J Pharmacol. 2019;176:S1‐S20. 10.1111/bph.14747 - DOI - PMC - PubMed
    1. Alexander SP, Kelly E, Marrion NV, et al. The Concise Guide to PHARMACOLOGY 2019/20: Catalytic receptors. Br J Pharmacol. 2019;176:S247‐S296. - PMC - PubMed

Publication types

MeSH terms